Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Glucophage XR RM (China vs Germany)
NCT05463094Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time and Maximum Observed Plasma Concentration. Started Jul 2022; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05463094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463094.